Aachen, Germany

Marco Bocola

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Marco Bocola in Glucose Oxidase Research

Introduction

Marco Bocola is a prominent inventor based in Aachen, Germany, known for his contributions to the field of biochemistry, particularly in the development of glucose oxidase variants. With a focus on improving blood glucose measurement techniques, Bocola has made significant strides that are beneficial for diabetes management.

Latest Patents

One of Bocola's key inventions is a patent for novel glucose oxidase (GOx) variants, identified for their unique amino acid substitutions. His patent details substitutions at positions T30V and I94V, as well as additional modifications in the amino acid sequence at select positions such as S53, A137, A173, A332, F414, and V560. These GOx variants demonstrate specificity for glucose while exhibiting reduced oxygen consumption rates, along with enhanced activity for alternative electron mediators. His innovation is not only groundbreaking in its chemical engineering aspect but also in the practical application via assay devices designed for improved blood glucose measurement.

Career Highlights

Marco Bocola currently works with Roche Diabetes Care, Inc., where he leverages his expertise in enzymology and biotechnology to develop solutions that can assist individuals living with diabetes. His focus on glucose oxidase research significantly enhances the accuracy and efficiency of blood glucose monitoring technologies.

Collaborations

Throughout his career, Bocola has collaborated with esteemed colleagues such as Hartmut Duefel and Erik Uwe Arango Gutierrez. Their combined efforts showcase a collaborative spirit that fosters innovation and leads to advancements in diabetes care technologies.

Conclusion

In summary, Marco Bocola's innovation in glucose oxidase variants stands as a testament to the impact that targeted research can have on healthcare. His work at Roche Diabetes Care, Inc. highlights a commitment to improving the lives of those affected by diabetes through advanced technological solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…